Brainstorm Cell Therapeutics Inc
brainstorm-cell.comWhat Do They Do?
Develops NurOwn, a patient-derived stem cell therapy for neurodegenerative diseases, including ALS, progressive multiple sclerosis and Alzheimer’s disease.
10-K for FY2025, filed Mar 31, 2026Brainstorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class…View ↗
NurOwn® technology is based on an innovative manufacturing protocol, which induces the differentiation of purified and expanded bone…View ↗
NurOwn® manufacturing involves a multi-step process that includes the following: harvesting and isolating undifferentiated stem cells from…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.9MView ↗
- ▲ +33% (Loss)
- vs −$2.9M in Q2 FY2025
-
Jul 30, 2026
Peter Pitts became Executive Chairman; Jacob Frenkel resigned as Board Chairman
Frenkel will serve as an advisor, and Pitts will lead daily strategic operations and the NurOwn program.
Sources
8-K, filed Jul 30, 2026
On July 24, 2026, the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) appointed Peter Pitts, a member…View ↗
Who Do They Compete With?
Competes with Corestem, Kadimastem, Coya, Rapa Therapeutics, AB Science, Ionis, Biogen, Neuraltus Pharma, and Neuvivo
10-K for FY2025, filed Mar 31, 2026There are several clinical trials underway evaluating experimental treatments for ALS, of which only one is a cell-based trials being…View ↗
Loading...
